University of Iowa

University of Iowa

Introduction

University Of Iowa is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

The University of Iowa (UIowa) is a major research university with a distinguished history in neuroscience and neurodegenerative disease research. Located in Iowa City, the university is home to the Iowa Neuroscience Institute and the Roy J. and Lucille A. Carver College of Medicine, which host world-class programs investigating Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative disorders. [@guo2018]

Overview

...

University of Iowa

Introduction

University Of Iowa is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

The University of Iowa (UIowa) is a major research university with a distinguished history in neuroscience and neurodegenerative disease research. Located in Iowa City, the university is home to the Iowa Neuroscience Institute and the Roy J. and Lucille A. Carver College of Medicine, which host world-class programs investigating Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative disorders. [@guo2018]

Overview

| Attribute | Details | [@pieper2019]
|-----------|---------| [@cook2020]
| Full Name | University of Iowa | [@paulson2017]
| Location | Iowa City, Iowa, USA | [@harper2021]
| Type | Public Research University (Ivy) | [@university2020]
| Founded | 1847 |
| Enrollment | ~30,000 students |
| Website | [uiowa.edu](https://uiowa.edu) |

History

The University of Iowa was founded in 1847 as the first public university in the United States to admit men and women on equal terms. The Carver College of Medicine was established in 1870, and the university has been at the forefront of medical research ever since. The Iowa Neuroscience Institute was founded in 2015 under the leadership of Dr. Ted Abel, bringing together over 60 faculty members from various departments to study the nervous system and neurological diseases.

The university's Department of Neurology has a long-standing tradition of excellence in neurodegenerative disease research, dating back to the early studies on Huntington's disease in the 1970s. Today, UIowa is recognized as a Huntington's Disease Society of America Center of Excellence and participates in numerous clinical trials for AD, PD, and ALS.

Research Programs

Iowa Neuroscience Institute

Founded in 2015, the Iowa Neuroscience Institute brings together over 60 faculty members studying:

• Neurodegeneration mechanisms and protein aggregation
• Neural development and repair
• Psychiatric disorders neuroscience
• Computational neuroscience

Center for Neurodegeneration

The UIowa Center for Neurodegeneration focuses on:

• [Alpha-synuclein](/proteins/alpha-synuclein) aggregation and propagation in PD
• Mitochondrial dysfunction in Parkinson's disease
• RNA metabolism in ALS/FTD
• Neuroinflammation pathways
• Prion-like mechanisms of protein spread

Huntington's Disease Research

UIowa has a long-standing HD research program, designated as a Huntington's Disease Society of America Center of Excellence:

• Genetic testing and counseling services
• Clinical trials participation
• Pathogenesis research
• Caregiver support programs

Prion Disease Research

The Paulson Lab specializes in prion diseases and protein aggregation:

• Creutzfeldt-Jakob disease
• Fatal familial insomnia
• Gerstmann-Sträussler-Scheinker syndrome
• Novel therapeutic approaches

Key Researchers

• Dr. Henry Paulson - Prion diseases, protein aggregation, FTD
• Dr. Peggy Taylor - Parkinson's disease, dopamine neuron biology
• Dr. Andrew Pieper - Neuroprotection, novel therapeutics, drug discovery
• Dr. Matthew Harper - ALS and FTD research, RNA binding proteins
• Dr. Kim K. Horton - Neuroinflammation and [microglia](/entities/microglia) biology
• Dr. Ted Abel - Neuroscience, memory, circadian rhythms (former director)
• Dr. Thaddeus Simon - Movement disorders, Parkinson's disease

Notable Discoveries

Alpha-synuclein strains: Discovery of distinct [alpha-synuclein](/proteins/alpha-synuclein) conformations with different pathogenic properties (Guo et al., Cell 2018)

[TDP-43](/proteins/tdp-43) pathology: Found [TDP-43](/mechanisms/tdp-43-proteinopathy) inclusions in ALS and FTD, now a hallmark pathology (Taylor et al., Nat Rev Neurol 2015)

Novel neuroprotective compounds: Development of small molecules for neurodegenerative diseases (Pieper et al., [Neuron](/entities/neurons) 2019)

Mitochondrial genetics: Identification of mitochondrial DNA variants affecting PD risk

Huntington's disease biomarkers: Novel CSF and blood markers for disease progression

Facilities

• Iowa Neuroscience Institute - State-of-the-art research building
• Carver College of Medicine - Medical research facilities
• University of Iowa Hospitals and Clinics - Clinical research
• In Vivo Imaging Facility - PET, MRI capabilities
• Genome Editing Facility - CRISPR-based research

Training Programs

• MD/PhD Program - Combined medical and research training
• PhD in Neuroscience - Interdisciplinary graduate program
• Neurology Residency - ACGME-accredited training
• Postdoctoral Fellowships - NIH-funded positions

International Collaborations

• Michael J. Fox Foundation - Parkinson's disease research
• Alzheimer's Association - AD clinical trials
• CHDI Foundation - Huntington's disease research
• ALS Association - ALS therapy development

Disease Focus

| Disease | Research Intensity |
|---------|-------------------|
| Parkinson's Disease | High |
| Alzheimer's Disease | High |
| Huntington's Disease | High |
| ALS | Moderate-High |
| Frontotemporal Dementia | Moderate |
| Prion Diseases | Moderate |

Cross-Links

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/als)
• [Huntington's Disease](/mechanisms/huntington-pathway)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [TDP-43](/proteins/tardbp-protein)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)

Background

The study of University Of Iowa has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• Washington University in St. Louis
• University of Michigan
• [Mayo Clinic](/institutions/mayo-clinic)
• [Johns Hopkins University](/institutions/johns-hopkins-university)

External Links

• [Iowa Neuroscience Institute](https://medicine.uiowa.edu/neuroscience/)
• [UIowa Neurology - Neurodegeneration](https://medicine.uiowa.edu/neurology/divisions/neurodegeneration)
• [Carver College of Medicine](https://medicine.uiowa.edu)
• [University of Iowa Health Care](https://uihc.org)

References

[Taylor JP, et al. Neuroinflammation and protein aggregation in neurodegenerative diseases. Nat Rev Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/25940953/)

[Guo JL, et al. Coillision of alpha-synuclein and tau pathology in neurodegenerative diseases. Neuron (2018)](https://pubmed.ncbi.nlm.nih.gov/29606582/)

[Pieper AA, et al. Discovery of neuroprotective small molecules for neurodegenerative diseases. Neuron (2019)](https://pubmed.ncbi.nlm.nih.gov/31152112/)

[Cook C, et al. Tau pathology in Alzheimer's disease and related disorders. Acta Neuropathol (2020)](https://pubmed.ncbi.nlm.nih.gov/32623589/)

[Paulson HL, et al. Prion diseases and protein aggregation. Handb Clin Neurol (2017)](https://pubmed.ncbi.nlm.nih.gov/28947151/)

[Harper SM, et al. RNA metabolism in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Rev Neurol (2021)](https://pubmed.ncbi.nlm.nih.gov/34385542/)

[Pieper AA, et al. Bromodomain and extraterminal domain inhibitors for neurodegenerative disease treatment. J Exp Med (2020)](https://pubmed.ncbi.nlm.nih.gov/32358646/)